The prevalence of Melanoma is highMelanoma is 100% curable if detected before it invades the dermis
If melanoma is found when it is early (less than 1 mm deep), the chance of 5-year survival is greater than 95%. However if it is found at a later stage, mortality rates decrease significantly.Dermatologists need help identifying early melanoma
Studies show that dermatologists miss (i.e., elect not to biopsy) between 20% to 30% of early melanomas.
An Unmet Need
MelaFind® meets an unmet
While trained dermatologists are able to recognize many advanced melanomas and rule out banal lesions, many patients present with clinically atypical pigmented skin lesions that have one or more characteristics of melanoma, but are not overtly obvious. The clinical challenge for dermatologists lies in accurately identifying the melanomas amongst these clinically atypical pigmented skin lesions at the stage when the disease is highly curable. Subjectivity and not being able to appreciate complex cellular patterns below the surface are among the reasons that melanomas are missed. MelaFind® can help.
MelaFind® correctly called more normal moles “Low Disorganization” than dermatologists, which could mean fewer biopsies of moles that were histologically benign.7
MelaFind® is the first objective, 100% automated device for the evaluation of clinically atypical pigmented skin lesions. The MelaFind® data requires no interpretation, but rather, incorporation of the data, which allows for a more informed biopsy decision. It provides unambiguous output (lesions that cannot be evaluated by MelaFind® are clearly designated as such to the operator) based on the complex cellular patterns below the skin’s surface for the first time, giving dermatologists more information when considering a biopsy.
Melanoma in situ
In the Adjunctive Reader study, MelaFind® demonstrated a 25% higher sensitivity compared to the human eye. Within this study, 44% of melanomas were in situ and invasive melanomas had a median Breslow thickness of 0.39 mm.